Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03852823 | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours | unknown | Phase 1 | 192 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03795597 | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)(BuMelCarAuto) | unknown | Phase 1 / Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 |
| clinicaltrials |
| NCT04796675 | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | unknown | Phase 1 | 27 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | unknown | Phase 1 / Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04796857 | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL | unknown | Phase 1 / Phase 2 | 30 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04594135 | Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies(CD5CAR-T) | unknown | Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Mar 2, 2021 | clinicaltrials |
| NCT04003168 | Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Mar 1, 2021 | clinicaltrials |
| NCT04762745 | The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04558853 | Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma | unknown | Phase 1 | 12 | Karolinska University HospitalOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03262298 | Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies | unknown | Phase 1 / Phase 2 | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT03156101 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 24 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02546739 | Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL | unknown | Phase 1 | 100 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04723914 | Dual Target CAR-T Cells in B-cell Lymphoma(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | YuLiOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04296461 | Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 20 | UWELL BiopharmaINDUSTRY | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03271515 | Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL | unknown | Phase 1 | 20 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04480788 | CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study | unknown | Phase 1 | 9 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04653649 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT02772198 | T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 300 | Sheba Medical CenterOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03921879 | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma | unknown | Phase 1 | 50 | Oncotartis, Inc.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT03716856 | Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma | unknown | Phase 1 | 11 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03711864 | Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma | unknown | Phase 1 | 15 | Peking Union Medical College HospitalOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04004637 | CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04537442 | Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT04486872 | An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection | unknown | Phase 1 | 18 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04500431 | Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM | unknown | Phase 1 | 10 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500561 | YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial | unknown | Phase 1 / Phase 2 | 28 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 5, 2020 | clinicaltrials |
| NCT03778619 | MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin | unknown | Phase 1 / Phase 2 | 9 | GC Cell CorporationINDUSTRY | 1 | Jul 28, 2020 | clinicaltrials |
| NCT04275583 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04120350 | R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty(REMLA) | unknown | Phase 1 / Phase 2 | 47 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT04337606 | Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02951728 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma(DR-CHOP) | unknown | Phase 1 / Phase 2 | 58 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT04295018 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03051841 | CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03150316 | CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT04206943 | Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL(ISIKOK-19) | unknown | Phase 1 / Phase 2 | 24 | Acibadem UniversityOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03015922 | Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma(MUKeleven) | unknown | Phase 1 | 4 | University of LeedsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT04163575 | Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL | unknown | Phase 1 / Phase 2 | 100 | Kecellitics Biotech Company LtdINDUSTRY | 0 | Dec 23, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04194931 | Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 20 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03720496 | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy | unknown | Phase 1 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04026100 | CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | unknown | Phase 1 | 9 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03836690 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation(ToTem) | unknown | Phase 1 | 18 | University College, LondonOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02836834 | Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors | unknown | Phase 1 | 33 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03018405 | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications(THINK) | unknown | Phase 1 / Phase 2 | 146 | Celyad Oncology SAINDUSTRY | 2 | Sep 19, 2019 | clinicaltrials |
| NCT03618602 | Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients | unknown | Phase 1 | 30 | Shanghai Theorion Pharmaceutical Co Ltd.INDUSTRY | 1 | Sep 19, 2019 | clinicaltrials |
| NCT03497533 | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19(Trident19-H) | unknown | Phase 1 / Phase 2 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT03991559 | A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas | unknown | Phase 1 | 20 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT04008394 | Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies | unknown | Phase 1 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04026269 | Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen | unknown | Phase 1 / Phase 2 | 30 | Han weidongOTHER | 1 | Jul 19, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2021source: clinicaltrials